key: cord-1011179-m7j0g0nd
authors: Krzywicka, Katarzyna; Heldner, Mirjam R.; Sánchez van Kammen, Mayte; van Haaps, Thijs; Hiltunen, Sini; Silvis, Suzanne M.; Levi, Marcel; Kremer Hovinga, Johanna A.; Jood, Katarina; Lindgren, Erik; Tatlisumak, Turgut; Putaala, Jukka; Aguiar de Sousa, Diana; Middeldorp, Saskia; Arnold, Marcel; Coutinho, Jonathan M.; Ferro, José M.
title: Post‐SARS‐CoV‐2‐vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency
date: 2021-08-04
journal: Eur J Neurol
DOI: 10.1111/ene.15029
sha: 2aaba9bdc05c6f1a9e65c290737903ff6607e386
doc_id: 1011179
cord_uid: m7j0g0nd

BACKGROUND AND PURPOSE: Cerebral venous sinus thrombosis (CVST) has been described after vaccination against SARS‐CoV‐2. The clinical characteristics of 213 post‐vaccination CVST cases notified to the European Medicines Agency are reported. METHODS: Data on adverse drug reactions after SARS‐CoV‐2 vaccination notified until 8 April 2021 under the Medical Dictionary for Regulatory Activities Term ‘Central nervous system vascular disorders’ were obtained from the EudraVigilance database. Post‐vaccination CVST was compared with 100 European patients with CVST from before the COVID‐19 pandemic derived from the International CVST Consortium. RESULTS: In all, 213 CVST cases were identified: 187 after AstraZeneca/Oxford (ChAdOx1 nCov‐19) vaccination and 26 after a messenger RNA (mRNA) vaccination (25 with Pfizer/BioNTech, BNT162b2, and one with Moderna, mRNA‐1273). Thrombocytopenia was reported in 107/187 CVST cases (57%, 95% confidence interval [CI] 50%–64%) in the ChAdOx1 nCov‐19 group, in none in the mRNA vaccine group (0%, 95% CI 0%–13%) and in 7/100 (7%, 95% CI 3%–14%) in the pre‐COVID‐19 group. In the ChAdOx1 nCov‐19 group, 39 (21%) reported COVID‐19 polymerase chain reaction tests were performed within 30 days of CVST symptom onset, and all were negative. Of the 117 patients with a reported outcome in the ChAdOx1 nCov‐19 group, 44 (38%, 95% CI 29%–47%) had died, compared to 2/10 (20%, 95% CI 6%–51%) in the mRNA vaccine group and 3/100 (3%, 95% CI 1%–8%) in the pre‐COVID‐19 group. Mortality amongst patients with thrombocytopenia in the ChAdOx1 nCov‐19 group was 49% (95% CI 39%–60%). CONCLUSIONS: Cerebral venous sinus thrombosis occurring after ChAdOx1 nCov‐19 vaccination has a clinical profile distinct from CVST unrelated to vaccination. Only CVST after ChAdOx1 nCov‐19 vaccination was associated with thrombocytopenia.

Vaccination against SARS-CoV-2 has been initiated at an impressive [2] [3] [4] [5] [6] . This condition has been termed vaccine-induced immune thrombotic thrombocytopenia (VITT) and appears to be related to the ChAdOx1 nCov-19 and Ad26.COV2.S vaccines [2, 4, 7] .

The number of published post-SARS-CoV-2-vaccination CVST cases is small and there is a possibility of selective reporting of patients with VITT. Also, the characteristics of patients who developed CVST after SARS-CoV-2 vaccination have not yet been compared to patients with CVST from before the COVID-19 pandemic. Here, the clinical data of patients with CVST notified to the EMA after SARS-CoV-2 vaccination are reported and compared with a control group of CVST cases from before the COVID-19 pandemic.

The EMA granted the authors research access to the EudraVigilance database [8] . The EMA is the official institution of the European Economic Area (EEA) that regulates all drug-related activities within the European Union and one of its duties is to collect data on adverse drug reactions (ADRs) [9, 10] . EudraVigilance is a passive pharmacovigilance system hosted and maintained by the EMA in which all suspected ADRs from the marketing authorization holders and national competent authorities are collected [10] . Cases with the following 'reaction preferred terms' (RCPTs) of the Medical Dictionary for Regulatory Activities were considered to have CVST: 'cerebral venous thrombosis', 'cerebral venous sinus thrombosis', 'jugular vein thrombosis', 'superior sagittal sinus thrombosis', 'transverse sinus thrombosis' and 'cavernous sinus thrombosis'. In addition, cases with an RCPT that could potentially indicate CVST were screened (Table S1 ). Clinical data of each case with one of the RCPTs which could indicate a CVST were independently screened by two of three investigators (KK, MSK and TH), using information from the reported Data Elements available (Table S2 ).

Cases that were marked as 'potential CVST' by at least one of the investigators were adjudicated by a senior vascular neurologist (JMC), who made the final decision on whether or not to classify the case as CVST. After identification of the CVST cases, duplicates and cases that were reported from countries outside the European continent were excluded.

The following variables were considered as traditional CVST risk factors: cancer, hormone replacement therapy or oral contraceptive use, genetic thrombophilia and any concomitant infection.

Thrombocytopenia was defined as a platelet count of <150 × 10 3 /µl.

Cases were considered to have thrombocytopenia if platelet counts <150 × 10 3 /µl were reported in the 'Result Unstructured Data' in 7/100 (7%, 95% CI 3%-14%) in the pre-COVID-19 group. In the ChAdOx1 nCov-19 group, 39 (21%) reported COVID-19 polymerase chain reaction tests were performed within 30 days of CVST symptom onset, and all were negative. Of the 117 patients with a reported outcome in the ChAdOx1 nCov-19 group, 44 (38%, 95% CI 29%-47%) had died, compared to 2/10 (20%, 95% CI 6%-51%) in the mRNA vaccine group and 3/100 (3%, 95% CI 1%-8%) in the pre-COVID-19 group. Mortality amongst patients with thrombocytopenia in the ChAdOx1 nCov-19 group was 49% (95% CI 39%-60%).

Conclusions: Cerebral venous sinus thrombosis occurring after ChAdOx1 nCov-19 vaccination has a clinical profile distinct from CVST unrelated to vaccination. Only CVST after ChAdOx1 nCov-19 vaccination was associated with thrombocytopenia. Table S2 ) or if there was a RCPT 'thrombocytopenia' reported.

Cerebral venous sinus thrombosis cases reported in patients who received an adenovirus based vaccine (ChAdOx1 nCov-19 and Ad26.

COV2.S) were compared to cases reported for patients who received an mRNA vaccine (BNT162b2 and mRNA-1273). However, because there were no CVST cases after Ad26.COV2.S vaccination reported from European countries during the study period, the Ad26.COV2.S vaccine was disregarded from the analysis. Post-vaccination CVST cases were additionally compared to a control group of CVST patients diagnosed prior to the COVID-19 pandemic. Data for this control sample were derived from the International CVST Consortium, which is an academic collaboration established in 2015 with the aim of performing clinical research on CVST [11] [12] [13] [14] . CVST patients from three participating European hospitals (Table S4) 

A descriptive analysis was performed, calculating median and interquartile range for continuous variables, and counts and percentages for categorical variables. 95% confidence intervals (95% CI) were calculated for the following variables that were hypothesized to be different between the cases after adenovirus based vaccination and the other two groups: thrombocytopenia, concomitant venous thromboembolic events (VTE) and mortality. Confidence intervals were calculated using Wilson's method using the Hmisc package in R Studio 4.0.3.

Out of 2517 individual cases with at least one neurovascular ADR recorded in the EudraVigilance database, 213 CVST cases were identi- Table 1 ). The median interval between first reported administration of SARS-CoV-2 vaccine and CVST symptom onset was 9 days (IQR 5-13) in the ChAdOx1 nCov-19 group and 7 days (IQR 2-21) in the mRNA vaccine group. In the mRNA vaccine group, there were two patients who developed CVST 2 and 13 days after the second vaccination with BNT162b2 vaccine.

A traditional CVST risk factor was reported in 20 (11%) and four (15%) cases in the ChAdOx1 nCov-19 and mRNA vaccine groups, respectively, whereas a CVST risk factor was identified in 64 (64%) patients in the pre-COVID-19 cohort group (Table 1) . Amongst patients with thrombocytopenia in the ChAdOx1 nCov-19 group, 10 (9%) had an additional risk factor reported (see Table S3 ).

Thrombocytopenia was reported in 107/187 cases (57%, 95% CI 50%-64%) in the ChAdOx1 nCov-19 group, none in the mRNA vaccine group (95% CI 0%-13%) and 7/100 (7%, 95% CI 3%-14%) in the pre-COVID-19 CVST group. Amongst patients with thrombocytopenia in the ChAdOx1 nCov-19 vaccine group, the median of the lowest reported platelet count was 31 × 10 3 /µl (IQR 17-64, reported in 57/107 cases, 53%). Antibodies against platelet factor 4 were reported to be present in 15 cases in the ChAdOx1 nCov-19 group and in none in the mRNA vaccine group. There was no information on the number of patients tested for these antibodies.

In 22 patients (12%, 95% CI 8%-17%) in the ChAdOx1 nCov-19 vaccine group a concomitant VTE in addition to CVST was reported, compared to none in the mRNA vaccine group (95% CI 0%-13%) and nine (9%, 95% CI 5%-16%) in the pre-COVID-19 group ( Of the 117 patients with a reported outcome in the ChAdOx1 nCov-19 vaccine group, 44 (38%, 95% CI 29%-47%) had died, compared to 2/10 (20%, 95% CI 6%-51%) in the mRNA vaccine group and three (3%, 95% CI 1%-8%) in the pre-COVID-19 group. Amongst patients with thrombocytopenia in the ChAdOx1 nCov-19 vaccine group, 39/79 (49%, 95% CI 39%-60%) patients with reported outcome died (Table S3 ).

Comparing CVST cases from the EudraVigilance database with the pre-COVID-19 CVST cases, used as a historical control group, it was found that CVST reported after ChAdOx1 nCov-19 vaccination (i) was notified more frequently than after the BNT162b2 are needed [14] .

In conclusion, analysis of the EudraVigilance database shows that CVST occurring after ChAdOx1 nCov-19 vaccination has a clinical profile that is different from patients with CVST unrelated to vaccination. CVST after ChAdOx1 nCov-19 vaccination is associated with thrombocytopenia in approximately half of reported patients and has a high mortality rate. CVST cases occurring after application of mRNA vaccines were similar to pre-COVID-19 CVST cases, pointing towards background incidence rather than association with the vaccine.

The authors greatly acknowledge the support of the EMA staff with the analysis and interpretation of the data. 

Thijs van Haaps: Investigation (equal); validation (equal); writing-review and editing (equal)

Johanna A Kremer Hovinga: Investigation (equal); writing-review and editing (equal)

Jukka Putaala: Investigation (equal); writing-review and editing (equal)

writing-original draft (equal); writing-review and editing (equal)

Investigation (equal); writing-review and editing (equal)

writing-original draft (equal); writing-review and editing (equal)

Conceptualization (equal); investigation (equal); resources (equal); supervision (equal); writing-original draft (equal); writing-review and editing (equal)

writing-review and editing (equal)

Maintaining safety with SARS-CoV-2 vaccines

Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination

Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination

Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination

US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination

COVID-19 vaccine-associated cerebral venous thrombosis in Germany: a descriptive study

Recommendations for the clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopenia (VITT) for SARS-CoV-2 infections: communication from the ISTH SSC Subcommittee on Platelet Immunology

European Medicines Agency policy on access to EudraVigilance data for medicinal products for human use 23

EudraVigilance medicines safety database: publicly accessible data for research and public health protection

Late seizures in cerebral venous thrombosis

Acute symptomatic seizures in cerebral venous thrombosis

Risk of cerebral venous thrombosis in obese women

Official Website of the International Cerebral Venous Thrombosis Consortium

Cerebral venous thrombosis and portal vein thrombosis: a retrospective cohort study of 537,913 COVID-19 cases. medRxiv

Cerebral venous thrombosis and severe acute respiratory syndrome coronavirus-2 infection: a systematic review and meta-analysis

Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT)

The corresponding author affirms that this research complies with internationally accepted standards for research practice and reporting.